<code id='7FE3A16149'></code><style id='7FE3A16149'></style>
    • <acronym id='7FE3A16149'></acronym>
      <center id='7FE3A16149'><center id='7FE3A16149'><tfoot id='7FE3A16149'></tfoot></center><abbr id='7FE3A16149'><dir id='7FE3A16149'><tfoot id='7FE3A16149'></tfoot><noframes id='7FE3A16149'>

    • <optgroup id='7FE3A16149'><strike id='7FE3A16149'><sup id='7FE3A16149'></sup></strike><code id='7FE3A16149'></code></optgroup>
        1. <b id='7FE3A16149'><label id='7FE3A16149'><select id='7FE3A16149'><dt id='7FE3A16149'><span id='7FE3A16149'></span></dt></select></label></b><u id='7FE3A16149'></u>
          <i id='7FE3A16149'><strike id='7FE3A16149'><tt id='7FE3A16149'><pre id='7FE3A16149'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:hotspot    Page View:788
          A pair of scissor cuts four paper figures from a line of them — biotech coverage from STAT
          Adobe

          Sonata Therapeutics, a startup created two years ago through the merger of two Flagship Pioneering companies, has laid off about a third of its staff.

          The biotech laid off 21 employees in recent weeks, according to employee posts on social media and a company spokesperson. Sonata had around 63 employees before the layoffs.

          advertisement

          Sonata is just the latest in a series of startups laying off employees in order to stretch out their cash runways. Privately held startups have had a difficult time raising money during the recent biotech downturn, which has shown signs of abating in the last few months. But at this point, startups are still finding that private investors and venture capitalists are being cautious with their money as they wait to see if the downturn is truly over.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati
          In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

          CourtesyBristolMyersSquibbBristolMyersSquibbsaidthatitwouldpurchaseMiratiTherapeutics,makerofthecanc

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          3 questions for the future of Biden's cancer moonshot

          PresidentJoeBidenEliseAmendola/APWASHINGTON—ThelatestphaseofPresidentBiden’sCancerMoonshotinitiative